Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15511371 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDHTTTSHRKAT2B | |
| SCHEMBL25408333 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTHSD17B10ALDH1A1 | |
| SCHEMBL7802043 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2HPGDHTTKDM4EGAA | |
| SCHEMBL2754581 | 0.79 | ALDH1A1 (0.49) | SMN1; SMN2HPGDHTTTSHRBRD4 | |
| SCHEMBL2242400 | 0.78 | SMN1; SMN2 (0.38) | SMN1; SMN2HPGDHTTKDM4EGAA | |
| SCHEMBL913292 | 0.78 | SMN1; SMN2 (0.38) | SMN1; SMN2HPGDHTTKDM4EGAA | |
| SCHEMBL6238530 | 0.77 | NOTUM (0.40) | SMN1; SMN2HPGDHTTCASP3 | |
| SCHEMBL6234100 | 0.77 | NOTUM (0.40) | CASP3KDM4EGAAALDH1A1 | |
| SCHEMBL10495316 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTTSHRALDH1A1 | |
| SCHEMBL24796120 | 0.77 | MAPT (0.54) | SMN1; SMN2HPGDHTTTSHRKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114364393-A | Methods of treatment using G-CSF protein complexes | 光谱制药有限公司 | 2022-04-15 | — | — | CN | claimed |
| US-20200230253-A1 | CONJUGATE OF IDURONATE-2-SULFATASE | HANMl PHARM. CO., LTD. (KR) | 2020-07-23 | — | — | US | claimed |
| CN-111433221-A | Long-acting conjugates of glucagon-like peptide-2 (G L P-2) derivatives | 韩美药品株式会社 | 2020-07-17 | — | — | CN | claimed |
| EP-2963055-B1 | SITE-SPECIFIC INSULIN CONJUGATE | HANMI PHARM IND CO LTD (KR) | 2019-05-15 | — | — | EP | claimed |
| US-20160000931-A1 | SITE-SPECIFIC INSULIN CONJUGATE | HANMI PHARM. CO., LTD. (KR) | 2016-01-07 | — | — | US | claimed |
| EP-2963055-A1 | SITE-SPECIFIC INSULIN CONJUGATE | Hanmi Pharm. Co., Ltd. (KR) | 2016-01-06 | — | — | EP | claimed |
| CN-117615775-A | Therapeutic uses comprising combinations of triple agonists that are all active on glucagon, GLP-1 and GIP receptors | 韩美药品株式会社 | 2024-02-27 | — | — | CN | disclosed |
| WO-2024017379-A1 | PREPARATION METHOD FOR POLYETHYLENE GLYCOL CONJUGATE OF ACTIVE POLYPEPTIDE OR PROTEIN | 派格生物医药(苏州)股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| CN-110536899-B | Insulin analogue complex with reduced affinity for insulin receptor and uses thereof | 韩美药品株式会社 | 2023-12-12 | — | — | CN | disclosed |
| CN-117157094-A | Pharmaceutical composition for preventing or treating chronic kidney disease comprising glucagon derivative | 韩美药品株式会社 | 2023-12-01 | — | — | CN | disclosed |
| CN-116916969-A | Novel conjugates of immunostimulatory IL-2 analogues and methods of making the same | 韩美药品株式会社 | 2023-10-20 | — | — | CN | disclosed |
| US-20230330184-A1 | METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX | SPECTRUM PHARMACEUTICALS INC. (US) | 2023-10-19 | — | — | US | disclosed |
| CN-116847868-A | Pharmaceutical composition comprising GIP derivative or long-acting conjugate thereof for preventing or treating pulmonary diseases | 韩美药品株式会社 | 2023-10-03 | — | — | CN | disclosed |
| EP-2963055-B1 | SITE-SPECIFIC INSULIN CONJUGATE | HANMI PHARM IND CO LTD (KR) | 2019-05-15 | — | — | EP | disclosed |
| US-20160000931-A1 | SITE-SPECIFIC INSULIN CONJUGATE | HANMI PHARM. CO., LTD. (KR) | 2016-01-07 | — | — | US | disclosed |
| EP-2963055-A1 | SITE-SPECIFIC INSULIN CONJUGATE | Hanmi Pharm. Co., Ltd. (KR) | 2016-01-06 | — | — | EP | disclosed |
| CN-105143255-A | Improved method for preparing physiologically active polypeptide complex with high yield | HANMI PHARM IND CO LTD | 2015-12-09 | — | — | CN | disclosed |
| EP-1861125-A2 | CONJUGATES OF AN HGH MOIETY AND PEG DERIVATIVES | Nektar Therapeutics Al, Corporation (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20060233740-A1 | Conjugates of an hGH moiety and a polymer | NEKTAR THERAPEUTICS | 2006-10-19 | — | — | US | disclosed |
| WO-2006102659-A2 | CONJUGATES OF AN hGH MOIETY AND A POLYMER | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060233740-A1 | Conjugates of an hGH moiety and a polymer | GGH, NGLY1, FOLH1 | SMN1; SMN2 1754/4885HPGD 1123/4885HTT 94/4885 |
| US-20200230253-A1 | CONJUGATE OF IDURONATE-2-SULFATASE | IDUA, FCGR2A, CNDP2 | SMN1; SMN2 2403/4885HPGD 3317/4885HTT 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.